The real race isn't who lives longest — it's who patents the epigenetic reprogramming delivery system first, as ER-100's FDA clearance signals that "rejuvenation" just became a regulated therapeutic category, not sci-fi.
Longevity biotech is becoming a sovereign wealth play — Gulf states (WGS 2026 platform for Sinclair) + Silicon Valley capital are converging on life extension as a geopolitical asset, mirroring how AI compute became a national security resource.